Hemophilia is a rare genetic bleeding disorder caused by a deficiency in clotting factors VIII or IX. Those with severe hemophilia can experience repeated spontaneous internal bleeding episodes, leading to joint damage, muscle atrophy, and loss of mobility. Proper treatment with clotting factor concentrates can prevent or treat bleeding episodes. However, around 30% of severe hemophilia patients develop inhibitors against treatment. Effective management requires early prophylactic treatment, education, coordinated multidisciplinary care, and continued research.